alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 31.1

I,   Norman G. Plotkin, certify that:

1.   I have reviewed this Quarterly Report on Form 10-Q of Factory 2-U Stores,
     Inc. (the "registrant");

2.   Based on my knowledge, this report does not contain any untrue statement of
     a material fact or omit to state a material fact necessary to make the
     statements made, in light of the circumstances under which such statements
     were made, not misleading with respect to the period covered by this
     report;

3.   Based on my knowledge, the financial statements, and other financial
     information included in this report, fairly present in all material
     respects the financial condition, results of operations and cash flows of
     the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officers and I are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     a)  Designed such disclosure controls and procedures, or caused such
         disclosure controls and procedures to be designed under our
         supervision, to ensure that material information relating to
         the registrant, including its consolidated subsidiaries, is made known
         to us by others within those entities, particularly during the period
         in which this report is being prepared;

     b)  Evaluated the effectiveness of the registrant's disclosure controls and
         procedures and presented b in this report our conclusions about the
         effectiveness of the disclosure controls and
         procedures, as of the end of the period covered by this report based on
         such evaluations; and

     c)  Disclosed in this report any change in the registrant's internal
         control over financial reporting that occurred during the registrant's
         fourth quarter that has materially affected, or
         is reasonably likely to materially affect, the registrant's internal
         control over financial reporting.

5.   The registrant's other certifying officers and I have disclosed, based on
     our most recent evaluation of internal control over financial reporting, to
     the registrant's auditors and the Audit Committee of the registrant's Board
     of Directors:

     a)  All significant deficiencies and material weaknesses in the design or
         operation of internal a control over financial reporting which are
         reasonably likely to adversely affect the registrant's ability to
         record, process, summarize and report financial information; and

     b)  Any fraud, whether or not material, that involves management or other
         employees who have a significant role in the registrant's internal
         control.

Date: June 10, 2004


                                             /s/ Norman G. Plotkin
                                             ---------------------
                                             Norman G. Plotkin
                                             Chief Executive Officer
##### 



Exhibit 99.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Champion Enterprises, Inc. (the
Company) on Form 10-Q for the period ending March 29, 2003 as filed with the
Securities and Exchange Commission on the date hereof (the Periodic Report),
I, Phyllis A. Knight, Chief Financial Officer of the Company, certify, pursuant
to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of
2002, that:



| | (1) |  | The Periodic Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15
U.S.C. 78m or 78o(d)); and     
| | --- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------
|
| | (2) |  | The information contained in the Periodic Report fairly
presents, in all material respects, the financial condition and
results of operations of the Company.

|                                                                                                         | 
|-------------------------------------------------------------------------------------------------------- | 
|/s/ PHYLLIS A. KNIGHT

Phyllis A. Knight
Chief Financial Officer
Champion Enterprises, Inc.
May 12, 2003 | 

A signed original of this written statement required by Section 906 has
been provided to the Company and will be retained by the Company and furnished
to the Securities and Exchange Commission or its staff upon request.
§ 510.301 Records and reports concerning experience with animal feeds bearing or containing new animal drugs for which an approved medicated feed mill license application is in effect. Records and reports of clinical and other experience with the new animal drug will be maintained and reported, appropriately identified with the new animal drug application(s) or index listing(s) to which they relate, to the Center for Veterinary Medicine in duplicate in accordance with the following: ( a ) Immediately upon receipt by the applicant, complete records or reports covering information of the following kinds: ( 1 ) Information concerning any mixup in the new animal drug or its labeling with another article.
( 2 ) Information concerning any bacteriological or any significant chemical, physical, or other change or deterioration in the drug, or any failure of one or more distributed batches of the drug to meet the specifications established for it in the new animal drug application or request for determination of eligibility for indexing.
( b ) As soon as possible, and in any event within 15 working days of its receipt by the applicant, complete records or reports concerning any information of the following kinds: ( 1 ) Information concerning any unexpected side effect, injury, toxicity, or sensitivity reaction or any unexpected incidence or severity thereof associated with clinical uses, studies, investigations, or tests, whether or not determined to be attributable to the new animal drug, except that this requirement shall not apply to the submission of information described in a written communication to the applicant from the Food and Drug Administration as types of information that may be submitted at other designated intervals. *Unexpected* as used in this paragraph refers to conditions or developments not previously submitted as part of the new animal drug application or in support of the index listing or not encountered during clinical trials of the drug, or conditions or developments occurring at a rate higher than shown by information previously submitted as part of the new animal drug application or in support of the index listing or at a rate higher than encountered during such clinical trials.
( 2 ) Information concerning any unusual failure of the new animal drug to exhibit its expected pharmacological activity.
[40 FR 13807, Mar. 27, 1975, as amended at 54 FR 18280, Apr. 28, 1989; 72 FR 69121, Dec. 6, 2007]
38330.

#### MORRIS v. OWEN *et al.*

Decided July 11, 1960.

*73
      *James*Maddox, for plaintiff in error.

*Harry T.*Lawrence, contra.

Gardner, Presiding Judge.

The druggist knew, from the allegations of this petition, that the drug was habit forming; he knew that the sale of such drug without a renewal prescription was a violation of a Federal statute; he knew that the plaintiff’s wife was continuing to purchase the drug without such renewal prescription, and he further knew that the drug was for her own use, since it was sold pursuant to the original prescription made out by the physician for her use.

Under *Code*§ 84-1313, a pharmacist in this State is required to be a graduate of a recognized college of pharmacy and also to have had twelve months of practical experience before being licensed. It is accordingly not necessary to allege that a licensed pharmacist would know the effects of habit-forming drugs. The petition states that the plaintiff’s wife had to be committed to- Milledgeville State Hospital as a result of the addiction, and damages to the husband were properly alleged. The petition *does not allege that the husband knew of his wife’s continued use of the drug.*

The trial court erred in sustaining the general demurrers and dismissing the petition.

*Judgment reversed.*

*Townsend, Carlisle and Frankum, JJ., concur.*
[No. 20601-3-II.

Division Two.

November 21, 1997.]

#### Roger Hannum, *Appellant,*v. Katherine Baros Friedt, *as Director,*et al., *Respondents.*

Appeal from a judgment of the Superior Court for Thurston County, No. 94-2-00165-2, Wm. Thomas McPhee, J., entered March 25, 1996. *Affirmed*by unpublished opinion per Bridgewater, J., concurred in by Houghton, C.J., and Armstrong, J. Now published at 88 "Wn. App. 881.
Editorial Note on Part 328
Editorial Note: Nomenclature changes to part 328 appear at 69 FR 13717, Mar. 24, 2004.

§ 328.10 Alcohol. ( a ) Any over-the-counter (OTC) drug product intended for oral ingestion shall not contain alcohol as an inactive ingredient in concentrations that exceed those established in this part, unless a specific exemption, as provided in paragraph (e) or (f) of this section, has been approved.
( b ) For any OTC drug product intended for oral ingestion and labeled for use by adults and children 12 years of age and over, the amount of alcohol in the product shall not exceed 10 percent.
( c ) For any OTC drug product intended for oral ingestion and labeled for use by children 6 to under 12 years of age, the amount of alcohol in the product shall not exceed 5 percent.
( d ) For any OTC drug product intended for oral ingestion and labeled for use by children under 6 years of age, the amount of alcohol in the product shall not exceed 0.5 percent.
( e ) The Food and Drug Administration will grant an exemption from paragraphs (b), (c), and (d) of this section where appropriate, upon petition under the provisions of § 10.30 of this chapter. Appropriate cause, such as a specific solubility or manufacturing problem, must be adequately documented in the petition. Decisions with respect to requests for exemption shall be maintained in a permanent file for public review by the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
( f ) Ipecac syrup is exempt from the provisions of paragraph (d) of this section.
( g ) The following drugs are temporarily exempt from the provisions of paragraphs (b), (c), and (d) of this section: ( 1 ) Aromatic Cascara Fluidextract.
( 2 ) Cascara Sagrada Fluidextract.
( 3 ) Orally ingested homeopathic drug products.
[60 FR 13595, Mar. 13, 1995, as amended at 61 FR 58630, Nov. 18, 1996; 68 FR 24879, May 9, 2003; 88 FR 45066, July 14, 2023]
Office of Grants and Training 

Preparedness Directorate 

U.S. Department of Homeland Security 

Washington, DC 20531

G&T Information Bulletin 

No. 206 May 11, 2006 

TO All State Administrative Agency Heads 

All State Administrative Agency Points of Contact 

All State Homeland Security Directors 

All Urban Area Core City/Core County Points of Contact 

FROM: Tracy A. Henke 

Assistant Secretary, Office of Grants and Training 

SUBJECT: Temporary Suspension of Direct Exercise Support 

At the direction of DHS Secretary Chertoff, the Preparedness Directorate’s Office of Grants 

and Training (G&T) is providing direct support for two major exercise initiatives designed to 

address pressing national priorities: the Hurricane Preparedness Exercises (HPE) under way in 

five regions along the Gulf and East Coasts, and 75 full-scale exercises in states and urban 

areas to validate tactical interoperable communications plans (TICP). The HPE began in May 

and will continue through June. The TICP exercises also will begin this month and continue 

through September 30, 2006. 

 

Due to the large number and abbreviated timelines for these two exercise priorities, G&T’s 

Training and Exercise Division must refocus resources and exercise support teams on these 

priority initiatives. For this reason, G&T is temporarily suspending all new requests for direct 

exercise support. Jurisdictions that have already been approved for direct exercise support will 

not be affected by this suspension; the planning and execution of your exercise will continue as 

scheduled. 

Requests for direct support submitted after dissemination of this Information Bulletin will be 

held until further notice, reviewed in the order in which they are received, and approved based 

on the availability of resources. This includes requests for the following: 

- HSEEP Mobile Training Course 

- Direct Support Exercises (other than HPE and TICP) 

- Training and Exercise Plan Workshops 

The Direct Support Exercise Program will resume as soon as resources allow. In the interim, 

please direct questions to your G&T Exercise Manager or email questions to: hseep@dhs.gov.
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.122 Drugs for processing, repacking, or manufacturing. A drug in a bulk package, except tablets, capsules, or other dosage unit forms, intended for processing, repacking, or use in the manufacture of another drug shall be exempt from section 502(f)(1) of the act if its label bears the statement “Caution: For manufacturing, processing, or repacking”; and if in substantially all dosage forms in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement “Rx only”, or if in substantially all dosage forms in which it may be dispensed it is subject to section 503(f)(1) of the act, the statement “Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian”. This exemption and the exemption under § 201.120 may be claimed for the same article. However, the exemption shall not apply to a substance intended for a use in manufacture, processing, or repacking which causes the finished article to be a new drug or new animal drug, unless: ( a ) An approved new drug application or new animal drug application or a new animal drug index listing covers the production and delivery of the drug substance to the application or index listing holder by persons named in the application or in the request for determination of eligibility for indexing, and, for a new drug substance, the export of it by such persons under § 314.410 of this chapter; or
( b ) If no application is approved with respect to such new drug or new animal drug, and it is not listed in the index, the label statement “Caution: For manufacturing, processing, or repacking” is immediately supplemented by the words “in the preparation of a new drug or new animal drug limited by Federal law to investigational use”, and the delivery is made for use only in the manufacture of such new drug or new animal drug limited to investigational use as provided in part 312 or § 511.1 or § 516.125 of this chapter; or
( c ) A new drug application or new animal drug application or a request for addition to the index covering the use of the drug substance in the production and marketing of a finished drug product has been submitted but not yet approved, disapproved, granted, or denied, the bulk drug is not exported, and the finished drug product is not further distributed after it is manufactured until after the new drug application or new animal drug application is approved or the request for addition to the index is granted.
[41 FR 6911, Feb. 13, 1976, as amended at 41 FR 15844, Apr. 15, 1976; 50 FR 7492, Feb. 22, 1985; 55 FR 11576, Mar. 29, 1990; 57 FR 54301, Nov. 18, 1992; 67 FR 4906, Feb. 1, 2002; 72 FR 69119, Dec. 6, 2007]
Third District Court of Appeal

State of Florida 

Opinion filed June 29, 2022.

Not final until disposition of timely filed motion for rehearing.

________________

No. 3D21-1766

Lower Tribunal No. 20-13216 SP

________________

Alliance JJ Miami, LLC,

Appellant,

vs.

Josiah Coates,

Appellee.

An appeal from the County Court for Miami-Dade County, Gisela 

Cardonne Ely, Senior Judge.

Ainsworth + Clancy, PLLC, and Yamila Lorenzo, and Ryan M. Clancy, 

for appellant.

Josiah Coates, in proper person.

Before LOGUE, MILLER, and GORDO, JJ. 

MILLER, J.
2

Appellant, Alliance JJ Miami, LLC, challenges a final judgment entered

in favor of appellee, Josiah Coates, in the underlying small claims action. As 

relevant to this appeal, the underlying dispute concerned whether Coates 

was entitled to reimbursement of a $350 “early cancellation fee” assessed 

purportedly pursuant to a martial arts membership agreement. Following a 

bench trial, the lower tribunal determined that the fee was unauthorized 

under the circumstances. Our de novo review of the contract yields the 

identical conclusion. See D & E Real Est., LLC v. Vitto, 260 So. 3d 429, 433

(Fla. 3d DCA 2018) (“The interpretation of a contract is a question of law 

which is . . . subject to de novo review.”). The agreement contains no early 

cancellation fee provision. Instead, it only allows for the imposition of a $350 

fee “[i]f the payment responsibilities stipulated in this contract are not 

fulfilled.” Declining to engraft an additional obligation into the contract and 

further finding that the conclusion by the trial court that the parties rescinded 

the original term of the contract in favor of a month-to-month option,

rendering Coates compliant with payment obligations, is amply supported by 

competent, substantial evidence, we affirm in all respects. See Fed. Nat’l 

Mortg. Ass’n v. Morton, 196 So. 3d 428, 431 (Fla. 2d DCA 2016) (“[W]hether 

a party has substantially complied with or performed a contract term remains 

a question of fact.”). 
3

Affirmed.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM JASON
INCORPORATED CONSOLIDATED BALANCE SHEET AT JUNE 27, 1997, AND CONSOLIDATED
INCOME STATEMENT FOR THE SIX MONTH PERIOD ENDED JUNE 27, 1997,  AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<CIK> 0000813471
<NAME> JASON INCORPORATED
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-26-1997
<PERIOD-START>                             DEC-28-1996
<PERIOD-END>                               JUN-27-1997
<CASH>                                            2036
<SECURITIES>                                         0
<RECEIVABLES>                                    63379
<ALLOWANCES>                                         0<F1>
<INVENTORY>                                      37492
<CURRENT-ASSETS>                                129681
<PP&E>                                          159945
<DEPRECIATION>                                   71915
<TOTAL-ASSETS>                                  307577
<CURRENT-LIABILITIES>                            75796
<BONDS>                                         113252<F2>
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         34687
<OTHER-SE>                                       65551
<TOTAL-LIABILITY-AND-EQUITY>                    307577
<SALES>                                         248487
<TOTAL-REVENUES>                                248487
<CGS>                                           200051
<TOTAL-COSTS>                                   200051
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                5199
<INCOME-PRETAX>                                   8993
<INCOME-TAX>                                      3507
<INCOME-CONTINUING>                               5486
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      5486
<EPS-PRIMARY>                                      .27
<EPS-DILUTED>                                        0<F3>
<FN>
<F1>COMPANY PRESENTS RECEIVABLES ON A NET BASIS IN COMPLIANCE WITH ARTICLE 10
REGULATION S-X.
<F2>INCLUDES ALL NON-CURRENT PORTION OF DEBT OBLIGATIONS.
<F3>NOT REPORTED.
</FN>
        

</TABLE>
Sh:J-001

16

Base from U.S. Geological Survey 1:24,000 and 

Mississippi River Commission 1:62,500 quadrangles

North American Datum of 1983

90°00' 89°45'

Approximate eastern limits of

the Jackson-upper Claiborne

confining unit

Approximate eastern limit of

35°15'

90°15'

35°00'

0 5 MILES

0 5 KILOMETERS

ARKANSAS TENNESSEE

MISSISSIPPI

Study area

EXPLANATION

180

Memphis Light, Gas and Water

Division well field and name

Potentiometric contour—Shows

altitude at which water level would have

stood in tightly cased wells. Dashed

where approximately located. Hachures

indicate depression. Contour interval

10 feet. Datum is National Geodetic Vertical

Datum of 1929 (NGVD 29)

Well for which water-level measurement 

made in October 2000 was used as control—

Number corresponds to map well number in 

table 1, and station names (Sh:J-001, for 

example) identify wells shown on figure 5

DAVIS

MORTON

MALLORY

LICHTERMAN

ALLEN

DAVIS

SHEAHAN

McCORD

SHAW

Walls

West Memphis

M emp h i s

Horne Lake

Olive Branch

Braden

Arlington

Cordova

Millington

Bartlett

Germantown

Collierville

FAYETTE CO

MARSHALL CO

64

51

55

240

57

72

64

40

70 79

51 14

78

70

79

14

61

40

ARKANSAS

TENNESSEE

ARKANSAS

MISSISSIPPI

Loosahatchie River

River

MISSISSIPPI

RIVER

Nonconnah Creek

M emp h i s

TIPTON CO

SHELBY CO

SHELBY CO

DESOTO CO

MISSISSIPPI CO

SHELBY CO

CRITTENDON CO

O

C

E

T

T

E

YAF

O

C

Y

B

L

E

H

S

55

150

160

170

190

200

180

210

220

230

240

250

260

270

140

130

190

210

220

230

240

250

180

170

150

170

160

Fa:R-002

Sh:J-001

Sh:O-001

Sh:Q-001

Sh:P-076

200

210

180

190

170

150

130

160

170

190

200

210

220

230

240

250

260

240

240

180

170

190

220

230

240

260

73

72

40

37

34

24

2

106

104

103

101

99

98

96

95

93

92

91

85

84

80

79

78

76

71

68

66 65

64

62

60

59

57

56

55

53

52

51

44

42

36

35

32

31

30

29

27

26

22

20

17 19

16

14

70

25

82

13

3

1

4

8

6

13

23

Mississippi

embayment

Figure 1. Altitude of the potentiometric surface of the Memphis aquifer in the Memphis area, Tennessee, October 2000.
[No. 39867-9-I.

Division One.

December 22, 1997.]

#### The State of Washington, *Respondent,*v. D.J.S., *Appellant.*

Appeal from a judgment of the Superior Court for King County, No. 96-8-06182-6, Richard A. Jones, J., entered December 11, 1996. *Affirmed*by unpublished per curiam opinion.